Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C25H36N2O8 |
| Molecular Weight | 492.5619 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(O)=C(O)C=C1C(=O)OC[C@H](CNC(C)(C)CNC(=O)C2CCOC2)OC(=O)C3(C)CC3
InChI
InChIKey=ANXXSWNMHQHOQC-DJNXLDHESA-N
InChI=1S/C25H36N2O8/c1-15-9-19(28)20(29)10-18(15)22(31)34-13-17(35-23(32)25(4)6-7-25)11-27-24(2,3)14-26-21(30)16-5-8-33-12-16/h9-10,16-17,27-29H,5-8,11-14H2,1-4H3,(H,26,30)/t16?,17-/m0/s1
| Molecular Formula | C25H36N2O8 |
| Molecular Weight | 492.5619 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Othera Pharmaceuticals originally developed OT-730 (now known as QLT 091568) as an oculoselective beta-blocker for reducing the elevated intraocular pressure associated with glaucoma. OT-730 was involved in phase II clinical trial in patients with ocular hypertension or open-angle glaucoma. However, these studies were discontinued. At December 30, 2009, QLT Inc. acquired OT-730.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:08 GMT 2023
by
admin
on
Sat Dec 16 11:32:08 GMT 2023
|
| Record UNII |
5WVS67PLAL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5WVS67PLAL
Created by
admin on Sat Dec 16 11:32:08 GMT 2023 , Edited by admin on Sat Dec 16 11:32:08 GMT 2023
|
PRIMARY | |||
|
OT-730
Created by
admin on Sat Dec 16 11:32:08 GMT 2023 , Edited by admin on Sat Dec 16 11:32:08 GMT 2023
|
PRIMARY | The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular hypertension. It will be compared with commercial timolol and placebo eye drops. | ||
|
870809-51-1
Created by
admin on Sat Dec 16 11:32:08 GMT 2023 , Edited by admin on Sat Dec 16 11:32:08 GMT 2023
|
PRIMARY | |||
|
11554979
Created by
admin on Sat Dec 16 11:32:08 GMT 2023 , Edited by admin on Sat Dec 16 11:32:08 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Anti-glaucoma, Anti-hyper-tensive, Small molecule; Mechanism of Action: Beta-adrenergic receptor antagonist; Highest Development Phase: Discontinued for Glaucoma, Ocular hypertension;
Most Recent Events: 03 Nov 2010 Discontinued - Phase-I/II for Glaucoma in USA (Ophthalmic), 30 Dec 2009 QLT acquires OT 730 from Othera Pharmaceuticals, 19 Sep 2008 Phase-I/II clinical trials in Glaucoma in USA (Ophthalmic)
|
||
|
ACTIVE MOIETY |
Development Status and FDA Approval Process for OT-730:
OT-730 is a novel, internally developed next generation topical beta-blocker designed to lower intra-ocular pressure (IOP), the leading risk factor for developing glaucoma.
|
